Top Banner
WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014
39

WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Dec 16, 2015

Download

Documents

Isabel Fox
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

WRHA Palliative Care Program

Dr. M. Harlos, Medical DirectorL. Embleton, Program Director

April 30, 2014

Page 2: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

http://palliative.info

Page 3: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.
Page 4: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

The presenters have no conflicts of interest to disclose

Page 5: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Objectives

• To provide an overview of the services offered by the WRHA Palliative Care program

• To review considerations for Respiratory Therapists in caring for palliative patients

Page 6: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Palliative Care is an approach to care which focuses on

comfort and quality of life for those affected by life-

limiting/life-threatening illness. Its goal is much more

than comfort in dying; palliative care is about living,

through meticulous attention to control of pain and

other symptoms, supporting emotional, spiritual, and

cultural needs, and maximizing functional status.

Page 7: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Role of WRHA Palliative Care Program

• WRHA Palliative Care Program is a clinical program that:– Provides and promotes quality palliative care for

patients/families with life limiting/threatening illnesses

– Provides support to health care teams providing care to palliative patients in any care setting

Page 8: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Role of WRHA Palliative Care Program

Two streams of service provided:

• Consultation

• Registration

Page 9: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Consultative Services• available to any patient with a life-limiting/threatening

illness, at any time in the illness trajectory, in any care setting for:

1. Symptom management2. Assistance with planning care3. Clarifying goals of care

• provided by inter-professional team members:– Palliative Care Physician– Palliative Care Clinical Nurse Specialist– Psycho-social Support Specialist

Page 10: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Consultative Services

To access consult service:• During business hours, all consults should be

directed to Palliative Care Program204-237-2400

• After hours – MD to MD consults available 24 hours a day through St. Boniface Paging

204-237-2053

Page 11: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Registration on Program

Patients can be “registered” on the Palliative Care Program if they meet program criteria:

– Prognosis of less than 6 months (approximately)– No longer receiving aggressive treatment which

requires on-going monitoring for and treatment of serious complications

– Have chosen a comfort-focused approach including a decision to decline attempted resuscitation

Page 12: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Registration on ProgramOnce registered with the program, patients are eligible for:

– Case management through Palliative Care Coordinator– Access to Community Palliative Care Nursing 24/7

• Palliative Care Nurses have access to Palliative Care Physician

– Admission to Palliative Care Units (PCU) and Hospice – if bed available

– Enrollment on Provincial Palliative Care Drug Access Program

Page 13: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Inpatient Care settings

Palliative Care units:– St. Boniface Hospital – 15 beds

• Tertiary Care Facility

– Riverview Health Centre – 30 beds

Hospices:– Grace Hospice – 12 beds– Jocelyn House – 4 beds

Page 14: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Community Palliative Care Program

• Approximately 400 patients at any one time• Each community team considers patients in their

area as their “ward”– Inclusive of all care settings – home, acute care and long

term care– Team meetings are held to discuss patient care needs

(rounds)• Focus on meeting needs in a proactive way

– Opportunity to strengthen networks with other care teams to support patients and families including the opportunity to model “palliative care”

Page 15: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

PCHs

PCHs

PCHs

NortheastNorthwest

South

Central

Patients at home

Home

PCHs

Patients at home

Patients at home

7 Oaks

HSC

VGH

ConcordiaGrace

CommunityClinics

CommunityClinics

CommunityClinics

Community Teams:• Community

Nurses• CNS• MD• Coordinator• Psychosocial

Page 16: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Pediatric Palliative Care

• Established in 2006– Services provided by physician and CNS

• Consultative service –no dedicated beds

• ~ 80 new patients each year

Page 17: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Diagnosis ofLife-Limiting

Illness

Transitioning to Palliative

Palliative

Consult Service

Community Palliative Nursing

• Case Coordinator• Admission Eligibility• Medication Coverage

• comfort-focused• prognosis “6 mo. or less”• some treatment limitations

(DNAR, no TPN, no chemoTx with high adverse effects

• aggressive, often toxic treatment focused on cure or life-prolonging disease modification

Page 18: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Considerations For The

Respiratory Therapist In Caring

For Palliative Patients

Page 19: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• Initiating and maintaining ventilatory support

• Setting up and supporting O2

• Educate patient, families, involved health care team

• Withdrawing ventilatory support

• Withdrawing O2

• Transport of palliative patients

• Nebulized meds (includinglidocaine)

Resp. Therapy

Palliative Care

SharedCare

Page 20: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

1. Role of O2 therapy in palliative patients

2. Noninvasive ventilation in ALS

3. Role of opioids in palliation of dyspnea

4. Transport of dying patients; role of Health Care Directive, ACP

5. Withdrawal of life-sustaining treatments – ventilatory support (invasive and noninvasive), oxygen

Specific Issues

Page 21: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• not a straightforward issue

• “hypoxia kills” – a common mantra in medical care

• should also be mindful that “supplemental O2 prolongs the natural dying process”

• the awake hypoxic patient feels less air hunger and does better physiologically with O2 supplementation

• the unconscious/comatose patient does not likely experience air hunger

• what about the awake, dyspneic, non-hypoxic palliative patient?

• studies of “air vs. O2” used room air by nasal prongs and are therefore not practical – “medical air” not available in clinical practice, and dyspnea is helped by cool air in nasopharynx

Role of O2 In Palliative Patients

Page 22: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• N = 32 non-dyspneic patients with Palliative Performance Scale ≤ 30% (median survival 9 days or less), at risk of developing dyspnea (CA lung, CHF, COPD, pneumonia)

• excluded if: mechanically ventilated, on high-flow O2 by FM; tracheostomy; experiencing respiratory distress at study entry

• SpO2, end-tidal CO2 measured; dyspnea assessed using Respiratory Distress Observation Scale

• patients were rotated blindly from O2, medical air, no-flow cannulae

• no difference in comfort between interventions

Page 23: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• results suggest that O2 need not be prescribed to patients who are near death and not exhibiting respiratory distress regardless of oxygen saturation.

• O2 can often be withdrawn when the patient makes a transition from terminal illness to imminent death, particularly as consciousness decreases.

• most patients tolerated a crossover from oxygen to air or no flow, however 3 patients experienced distress that was relieved by a return to oxygen. An inability to reliably predict which patient will

experience distress requires close clinical observation when withdrawing O2

Campbell et al continued…

Page 24: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• generally our practice is to focus on comfort, not oximetry

- good O2 sats, patient uncomfortable: intervention needed

- poor O2 sats, patient comfortable: no change needed

• often nasal prongs are better tolerated than mask, regardless of oximetry

• if a patient feels benefit with O2 even though room air oximetry is normal, we would use O2 if feasible

• in the unresponsive patient, consider tapering over a few hours as tolerated

Page 25: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• improved quality of life and survival, though this has not been demonstrated in bulbar onset ALS

• bulbar patients less tolerant of NIV (mouth leaks, sialorrhea)

Noninvasive Ventilation in ALS

Page 26: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.
Page 27: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.
Page 28: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• tendency to gradually increase its use – eventually to 24/7; the implications of this does not seem to be commonly discussed

• patient may be completely dependent on NIV, and unable to remove mask in event of machine or power failure

• the very patients who selected NIV rather than tracheostomy often find themselves on “life-support” with NIV, having to decide about withdrawal of ventilatory support

• conversations around end-of-life issues should be included when discussing any ventilatory support

• care setting for patients dependent on NIV need to address:- risk management around power / machine failure- ability to address symptoms in context of acute distress- ability to ensure comfort in context of withdrawal

Palliative Considerations Regarding NIV

Page 29: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Johnson MJ, Abernethy AP, and Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? J Pain Symptom Manage. United States; 2012;43(3):614-24.

Opioids And Dyspnea

Page 30: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• Regarding fear of respiratory depression –

• higher doses of opioids and benzodiazepines used in the withdrawal of life-sustaining treatment were not associated with a decreased time from withdrawal of life support to death

• Of 11 studies providing information on ABGs or O2 sat, only one study reported any significant changes in oxygenation after opioid administration

• Recommend that:

• Oral and/or parenteral opioids can provide relief of dyspnea.

• Opioids should be dosed and titrated for the individual patient with consideration of multiple factors (e.g., renal, hepatic, pulmonary function, and current and past opioid use) for relief of dyspnea.

American College Of Chest Physicians Consensus Statement On The Management Of Dyspnea In Patients

With Advanced Lung Or Heart Disease - 2010

Page 31: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea – 2012- Opioids have been the most widely studied agent in the

treatment of dyspnea. Short-term administration reduces breathlessness in patients with a variety of conditions, including advanced COPD, interstitial lung disease, cancer, and chronic heart failure

• Canadian Thoracic Society Clinical Practice Guideline 2011: Managing Dyspnea In Patients With Advanced Chronic Obstructive Pulmonary Disease- “We recommend that oral (but not nebulized) opioids be

used for the treatment of refractory dyspnea in the individual patient with advanced COPD”

Page 32: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Thorax. England; 2014;69(4):393-4.

• “Failure to properly treat chronic refractory breathlessness with opioids as outlined in specialist clinical guidelines is now substandard medical care and is also a breach of clinicians' ethical and legal duties to the patient” … “considered negligent”

• In addition to being a breach of professional, ethical and legal duties, failure to treat chronic refractory breathlessness adequately should be viewed as a breach of human rights.

Page 33: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

Common Concerns About Aggressive Use of Opioids at End-Of-Life

• How do you know that the aggressive use of opioids for dyspnea doesn't actually bring about or speed up the patient's death?

• “I gave the last dose of morphine and he died a few minutes later… did the medication cause the death?”

Page 34: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

1. Literature: the literature supports that opioids administered in doses proportionate to the degree of distress do not hasten death and may in fact delay death

2. Clinical context: breathing patterns usually seen in progression towards dying (clusters with apnea, irreg. pattern) vs. opioid effects (progressive slowing, regular breathing; pinpoint pupils)

3. Medication history: usually “the last dose” is the same as those given throughout recent hours/days, and was well tolerated

Page 35: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• may reduce overall oxygen demand

• “The administration of sedatives (midazolam and morphine) has been associated with decreases in oxygen demand and the attenuation of the cardiopulmonary response associated with increased work of breathing”

• see also: Endoh H et al; Effects of naloxone and morphine on acute hypoxic survival in mice. Crit Care Med; 1999;27(9):1929-33

- significantly lower oxygen consumption and improved survival in morphine treated rats subjected to acute hypoxic hypoxia

Page 36: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• risk of patient death during transport

• a Health Care Directive or Advance Care Plan is an important tool in preventing unwanted/inappropriate resuscitation attempts

• clear “what-if” plans need to be prepared, with involvement of patient and/or family

- e.g. limited bagging but no chest compressions, or allow natural death

• medications on hand for symptom management

Transporting Palliative Patients

Page 37: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

“Planning for Care In Advance”

2 Formal Processes

Health Care Directive• document outlining care

expectations• supported by legislation• 16+ yrs, competent• can name proxy• can be made on any

piece of paper• helps inform the ACP

process

Advance Care Planning

• Consensus-based process

• Patient/family/SDM* and Health Care Team

• Can be done if patient not able to participate

−cognitive impairment−children

* SDM = Substitute Decision Maker

Page 38: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• allowing the natural course of illness to unfold, in contrast to euthanasia

• RT not always included in the decision-making process, yet may still be involved – can be a difficult role to serve

• in a palliative care setting, we may need RT to help with the machine settings, extubation, perhaps suctioning

• comfort is paramount – biggest threat to comfort is air hunger

• preemptive & reactive opioids and sedatives are main pharmacologic interventions

• no specific predetermined dose – essentially only 3 possible doses: not enough; perfect; too much

- the correct dose is the one that is effective, avoids harm if possible, and is proportionate to the need

Withdrawal Of Ventilatory Support

Page 39: WRHA Palliative Care Program Dr. M. Harlos, Medical Director L. Embleton, Program Director April 30, 2014.

• “…respect and protect the legal rights of the patient, including the right to informed consent and refusal or withdrawal of treatment.”